Graeme Meintjes Selected Research

Rifampin (Rifampicin)

1/2022	Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
1/2022	Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
12/2021	Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
10/2021	Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis.
1/2021	Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial.
1/2021	Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM].
1/2021	Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis.
1/2021	Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis.
1/2021	Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.
1/2020	Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Graeme Meintjes Research Topics

Disease

88	Tuberculosis (Tuberculoses) 04/2022 - 02/2006
45	Immune Reconstitution Inflammatory Syndrome 01/2022 - 10/2006
39	Cryptococcal Meningitis 01/2022 - 10/2006
24	Infections 07/2022 - 09/2009
13	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 12/2022 - 09/2010
12	Coinfection 01/2022 - 01/2013
11	HIV Infections (HIV Infection) 11/2021 - 01/2008
11	Acquired Immunodeficiency Syndrome (AIDS) 10/2020 - 01/2009
8	Opportunistic Infections (Opportunistic Infection) 04/2020 - 08/2007
7	Pulmonary Tuberculosis 11/2021 - 11/2013
6	Meningeal Tuberculosis (Tuberculous Meningitis) 01/2021 - 12/2013
6	Inflammation (Inflammations) 01/2021 - 12/2013
5	Body Weight (Weight, Body) 01/2022 - 03/2014
5	Anemia 01/2016 - 07/2008
4	Meningitis 01/2018 - 01/2014
4	Drug-Related Side Effects and Adverse Reactions 10/2016 - 01/2013
4	Clinical Deterioration 01/2013 - 10/2006
3	Sepsis (Septicemia) 01/2022 - 01/2017
3	Disease Progression 01/2021 - 02/2015
3	Necrosis 10/2020 - 06/2009
3	Extensively Drug-Resistant Tuberculosis 12/2018 - 01/2014
2	COVID-19 07/2022 - 11/2020
2	Cryptococcosis 01/2022 - 11/2020
2	Cough 01/2022 - 01/2022
2	Lymphadenopathy 01/2022 - 01/2022
2	Respiratory Insufficiency (Respiratory Failure) 11/2020 - 03/2018
2	Pneumonia (Pneumonitis) 11/2020 - 03/2018
2	Hydrocephalus (Hydrocephaly) 04/2020 - 10/2017
2	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 01/2019 - 12/2015
2	Bacterial Infections (Bacterial Infection) 11/2018 - 01/2009
2	Neoplasms (Cancer) 11/2018 - 08/2016
2	Communicable Diseases (Infectious Diseases) 01/2018 - 10/2015
2	Chemical and Drug Induced Liver Injury 01/2016 - 03/2012
2	Vitamin D Deficiency 08/2014 - 10/2012
2	Central Nervous System Diseases (CNS Diseases) 01/2013 - 11/2010
1	Drug Hypersensitivity Syndrome 11/2022
1	Stevens-Johnson Syndrome (Lyell's Syndrome) 11/2022
1	Critical Illness (Critically Ill) 01/2022
1	Fever (Fevers) 01/2021

Drug/Important Bio-Agent (IBA)

24	Rifampin (Rifampicin)FDA LinkGeneric 01/2022 - 02/2006
19	AntigensIBA 01/2022 - 02/2006
17	Pharmaceutical PreparationsIBA 11/2022 - 01/2009
15	Fluconazole (Zonal)FDA LinkGeneric 01/2022 - 10/2006
15	lipoarabinomannan (LAM)IBA 01/2022 - 07/2014
13	CytokinesIBA 01/2021 - 07/2007
11	Amphotericin B (Amphotericin)FDA LinkGeneric 03/2018 - 07/2007
10	Linezolid (Zyvox)FDA Link 01/2022 - 01/2014
9	bedaquiline (R207910)IBA 12/2022 - 01/2014
9	Isoniazid (Ftivazide)FDA LinkGeneric 01/2022 - 02/2006
9	Prednisone (Sone)FDA LinkGeneric 01/2021 - 09/2010
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2017
6	Flucytosine (Ancobon)FDA Link 01/2022 - 07/2008
6	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2016 - 06/2009
5	liposomal amphotericin B FDA Link 01/2022 - 06/2015
5	InterleukinsIBA 01/2021 - 08/2015
4	VaccinesIBA 07/2022 - 12/2010
4	C-Reactive ProteinIBA 01/2022 - 01/2021
4	deoxycholate drug combination amphotericin BIBA 01/2022 - 12/2015
4	Hemoglobins (Hemoglobin)IBA 01/2022 - 03/2014
4	ChemokinesIBA 01/2020 - 10/2012
4	Matrix Metalloproteinases (MMPs)IBA 01/2018 - 05/2012
3	Clofazimine (Lamprene)FDA Link 12/2022 - 12/2018
3	FluoroquinolonesIBA 01/2022 - 01/2018
3	Interleukin-17 (Interleukin 17)IBA 01/2021 - 01/2016
3	dolutegravirIBA 01/2021 - 01/2020
3	Lactic Acid (Lactate)FDA LinkGeneric 01/2020 - 12/2015
3	Pyrazinamide FDA LinkGeneric 01/2019 - 10/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2017 - 06/2009
2	chinese inkIBA 01/2022 - 01/2014
2	Dihydrotachysterol (AT 10)IBA 01/2022 - 03/2014
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2017
2	Raltegravir Potassium FDA Link 01/2021 - 01/2021
2	GlucocorticoidsIBA 11/2018 - 09/2010
2	InflammasomesIBA 01/2017 - 09/2015
2	Interleukin-10 (Interleukin 10)IBA 11/2016 - 01/2016
2	InterferonsIBA 11/2016 - 06/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 10/2016 - 03/2012
2	hydroxide ionIBA 08/2014 - 10/2012
2	Interferon-gamma (Interferon, gamma)IBA 09/2009 - 06/2009
2	Antitubercular AgentsIBA 03/2009 - 01/2009
2	EnzymesIBA 11/2008 - 02/2006
1	N-(2-cyanoethylene)urea (BA 1)IBA 07/2022
1	Fluorescent Dyes (Fluorescent Probes)IBA 04/2022
1	AcidsIBA 01/2022
1	Cycloserine (Seromycin)FDA Link 01/2022
1	terizidoneIBA 01/2022
1	Integrase InhibitorsIBA 01/2022
1	OPC-67683IBA 01/2022
1	Aminosalicylic Acid (Rezipas)FDA Link 01/2022
1	Antifungal AgentsIBA 01/2022
1	Carbapenems (Carbapenem Antibiotics)IBA 01/2022

Therapy/Procedure

60	Therapeutics 12/2021 - 10/2006
35	Art Therapy 01/2022 - 01/2008
7	Highly Active Antiretroviral Therapy (HAART) 07/2012 - 10/2006
5	Injections 01/2022 - 01/2018
3	Aftercare (After-Treatment) 01/2022 - 01/2017
2	Treatment Delay 01/2021 - 01/2020
2	Immunotherapy 11/2020 - 06/2012
2	Ventriculoperitoneal Shunt 04/2020 - 10/2017
2	Drug Therapy (Chemotherapy) 10/2019 - 01/2009